The effect of the top 20 Alzheimer disease risk genes on gray‐matter density and FDG PET brain metabolism
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Introduction: We analyzed the effects of the top 20 Alzheimer disease (AD) risk genes on gray‐matter density (GMD) and metabolism. Methods: We ran stepwise linear regression analysis using posterior cingulate hypometabolism and medial temporal GMD as outcomes and all risk variants as predictors while controlling for age, gender, and APOE ε4 genotype. We explored the results in 3D using Statistical Parametric Mapping 8. Results: Significant predictors of brain GMD were SLC24A4/RIN3 in the pooled and mild cognitive impairment (MCI); ZCWPW1 in the MCI; and ABCA7, EPHA1, and INPP5D in the AD groups. Significant predictors of hypometabolism were EPHA1 in the pooled, and SLC24A4/RIN3, NME8, and CD2AP in the normal control group. Discussion: Multiple variants showed associations with GMD and brain metabolism. For most genes, the effects were limited to specific stages of the cognitive continuum, indicating that the genetic influences on brain metabolism and GMD in AD are complex and stage dependent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 1×
“Genes previously associated with the defining AD pathologic hallmark–amyloid pathology were also included in our study [35–37] (Supplementary Table 1).”
BackgroundNaj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 1×
“Genes previously associated with the defining AD pathologic hallmark–amyloid pathology were also included in our study [35–37] (Supplementary Table 1).”
BackgroundSelf-citationReiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366 · cited 1×
“With the help of imaging studies, APOE ε4 allele was found to be strongly associated with brain amyloidosis [14,15], atrophy [16], and hypometabolism [17,18].”
BackgroundGenome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Apolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857 · cited 1×
“Individuals with a single APOE ε4 allele have a threefold increase in AD risk, whereas homozygotes have a 12fold increase [12].”
BackgroundReiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
Landau, S. M., Harvey, D., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., Weiner, M. W., & Jagust, W. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.002 · Cited by 750
Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort
Risacher, S., Saykin, A., Wes, J., Shen, L., Firpi, H., & McDonald, B. (2009) · Current Alzheimer Research · doi:10.2174/156720509788929273 · Cited by 538 · cited 1×
“The downloaded images were aligned to each corresponding MRI image on a subjectby-subject basis in MNI space using SPM8, as previously described [46].”
MethodSelf-citationThe importance of neuritic plaques and tangles to the development and evolution of AD
Tiraboschi, P., Hansen, L. A., Thal, L. J., & Corey-Bloom, J. (2004) · Neurology · doi:10.1212/01.wnl.0000129697.01779.0a · Cited by 477 · cited 1×
“The clinical symptoms result from the deposition of two toxic proteins, b-amyloid (Ab) and tau, which give rise to neuritic plaques and neurofibrillary tangles, respectively [1].”
BackgroundRelationships between biomarkers in aging and dementia
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456 · cited 1×
“Finally, baseline mean FDG SUVR in bilateral posterior cingulate was extracted for each subject [48,49].”
MethodIncreased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology
GERAD consortium, Chapuis, J., Hansmannel, F., Gistelinck, M., Mounier, A., Van Cauwenberghe, C., Kolen, K. V., Geller, F., Sottejeau, Y., Harold, D., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.1 · Cited by 407 · cited 1×
“RIN3 also interacts with BIN1, which has recently been linked to tau pathology [89].”
BackgroundBeecham, G. W., Hamilton, K., Naj, A. C., Martin, E. R., Huentelman, M., Myers, A. J., Corneveaux, J. J., Hardy, J., Vonsattel, J.-P., Younkin, S. G., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004606 · Cited by 343
Expression of Novel Alzheimer’s Disease Risk Genes in Control and Alzheimer’s Disease Brains
Karch, C. M., Jeng, A. T., Nowotny, P., Cady, J., Cruchaga, C., & Goate, A. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050976 · Cited by 328
Yu, L., Chibnik, L. B., Srivastava, G. P., Pochet, N., Yang, J., Xu, J., Kozubek, J., Obholzer, N., Leurgans, S. E., Schneider, J. A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3049 · Cited by 290
Autosomal Recessive Causes Likely in Early-Onset Alzheimer Disease
Wingo, T. S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.221 · Cited by 265 · cited 1×
“Seventy to eighty percent of sporadic AD can be attributed to genetic risk [4,5].”
BackgroundGenetic Variation and Neuroimaging Measures in Alzheimer Disease
Biffi, A. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.108 · Cited by 222
Magnetic resonance imaging in Alzheimer’s disease neuroimaging initiative 2
Jack, C. R., Barnes, J., Bernstein, M. A., Borowski, B. J., Brewer, J., Clegg, S., Dale, A. M., Carmichael, O., Ching, C., DeCarli, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.002 · Cited by 220
Autophagic/lysosomal dysfunction in Alzheimer’s disease
Orr, M. E., & Oddo, S. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt217 · Cited by 199
Shulman, J. M., Imboywa, S., Giagtzoglou, N., Powers, M. P., Hu, Y., Devenport, D., Chipendo, P., Chibnik, L. B., Diamond, A., Perrimon, N., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt478 · Cited by 167 · cited 1×
“The total number of variants selected was 36.”
BackgroundFurney, S. J., Simmons, A., Breen, G., Pedroso, I., Lunnon, K., Proitsi, P., Hodges, A., Powell, J., Wahlund, L.-O., Kloszewska, I., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.123 · Cited by 157
Self-citationThe pursuit of susceptibility genes for Alzheimer's disease: progress and prospects
Sleegers, K., Lambert, J.-C., Bertram, L., Cruts, M., Amouyel, P., & Van Broeckhoven, C. (2010) · Trends in Genetics · doi:10.1016/j.tig.2009.12.004 · Cited by 129
ATP-binding cassette transporter A7 (ABCA7) loss of function alters Alzheimer amyloid processing
Satoh, K., Abe-Dohmae, S., Yokoyama, S., St George-Hyslop, P., & Fraser, P. E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.655076 · Cited by 128
Effect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification by APOE Genotype
Thambisetty, M., An, Y., Nalls, M., Sojkova, J., Swaminathan, S., Zhou, Y., Singleton, A. B., Wong, D. F., Ferrucci, L., Saykin, A. J., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.08.015 · Cited by 90 · cited 1×
“The total number of variants selected was 36.”
BackgroundSelf-citationLate-onset Alzheimer disease risk variants mark brain regulatory loci
Allen, M., Kachadoorian, M., Carrasquillo, M. M., Karhade, A., Manly, L., Burgess, J. D., Wang, C., Serie, D., Wang, X., Siuda, J., et al. (2015) · Neurology Genetics · doi:10.1212/nxg.0000000000000012 · Cited by 73
Relation of genomic variants for Alzheimer disease dementia to common neuropathologies
Farfel, J. M., Yu, L., Buchman, A. S., Schneider, J. A., De Jager, P. L., & Bennett, D. A. (2016) · Neurology · doi:10.1212/wnl.0000000000002909 · Cited by 64
Cuenco, K. T. (2008) · Archives of Neurology · doi:10.1001/archneur.65.12.1640 · Cited by 61
Effects of ApoE4 and maternal history of dementia on hippocampal atrophy
Andrawis, J. P., Hwang, K. S., Green, A. E., Kotlerman, J., Elashoff, D., Morra, J. H., Cummings, J. L., Toga, A. W., Thompson, P. M., & Apostolova, L. G. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.07.020 · Cited by 54
Self-citationLiao, F., Jiang, H., Srivatsan, S., Xiao, Q., Lefton, K. B., Yamada, K., Mahan, T. E., Lee, J.-M., Shaw, A. S., & Holtzman, D. M. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0006-y · Cited by 53
Cited by
Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.005 · Cited by 454
Self-citationCorces, M. R., Shcherbina, A., Kundu, S., Gloudemans, M. J., Frésard, L., Granja, J. M., Louie, B. H., Eulalio, T., Shams, S., Bagdatli, S. T., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00721-x · Cited by 358
Alzheimer’s Disease: An Updated Overview of Its Genetics
Andrade-Guerrero, J., Santiago-Balmaseda, A., Jeronimo-Aguilar, P., Vargas-Rodríguez, I., Cadena-Suárez, A. R., Sánchez-Garibay, C., Pozo-Molina, G., Méndez-Catalá, C. F., Cardenas-Aguayo, M.-D.-C., Diaz-Cintra, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043754 · Cited by 336
The role of ABCA7 in Alzheimer’s disease: evidence from genomics, transcriptomics and methylomics
De Roeck, A., Van Broeckhoven, C., & Sleegers, K. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01994-1 · Cited by 212
Initiative, A. D. N., Tan, M.-S., Yang, Y.-X., Xu, W., Wang, H.-F., Tan, L., Zuo, C.-T., Dong, Q., Tan, L., Suckling, J., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00755-7 · Cited by 71
Self-citation
Metadata
- Authors
- Stage, E., Duran, T., Risacher, S. L., Goukasian, N., Do, T. M., West, J. D., Wilhalme, H., Nho, K., Phillips, M., Elashoff, D., Saykin, A. J., Apostolova, L. G., & Initiative, A. D. N.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2016-01
- Volume
- 5
- Issue
- 1
- Pages
- 53-66
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W2563770392
- Cited by
- 48
- References
- 32
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.